Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.74 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.65 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.63 |
| ▸ | CSF1R | P07333 | 2/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13161988 | 0.89 | CYP11B2 (0.72) | BRAFSGMS2CYP11B2CYP11B1CSF1R | |
| SCHEMBL3942520 | 0.86 | BRAF (1.00) | BRAFCSF1RKITKDRMAPK14 | |
| SCHEMBL3934829 | 0.85 | BRAF (0.83) | BRAFCYP11B2CYP11B1CSF1RKIT | |
| SCHEMBL13161983 | 0.85 | CYP11B2 (0.77) | BRAFCYP11B2CYP11B1CSF1RKIT | |
| SCHEMBL3934041 | 0.84 | BRAF (0.63) | BRAFCYP11B2CYP11B1CSF1RKIT | |
| SCHEMBL13163097 | 0.84 | CYP11B2 (0.63) | BRAFSGMS2CYP11B2CYP11B1CSF1R | |
| SCHEMBL27180150 | 0.83 | ALDH1A1 (0.64) | BRAFCYP11B2CYP11B1CSF1RPOLB | |
| SCHEMBL30926718 | 0.83 | ALDH1A1 (0.64) | BRAFCYP11B2CYP11B1CSF1RPOLB | |
| SCHEMBL3943800 | 0.83 | BRAF (0.80) | BRAFCYP11B2CSF1R | |
| SCHEMBL3931806 | 0.82 | BRAF (0.78) | BRAFCSF1RKITKDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | BRAF 1984/4885SGMS2 4798/4885CYP11B2 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.